Back to mobile site

BofA on Alnylam (ALNY): 'AI-enabled diagnostics will help increase diagnosis rates'

March 24, 2026 3:10 PM EDT Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $460.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY)The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login